Last reviewed · How we verify
6EH³R³Z
Unfortunately, no information is available on the mechanism of action of 6EH³R³Z.
At a glance
| Generic name | 6EH³R³Z |
|---|---|
| Also known as | Ethambutol; isoniazid; rifampicin; pyrazinamide, triple dose isoniazid, triple dose rifampicin |
| Sponsor | Institute of Tropical Medicine, Belgium |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Further research is needed to determine the exact mechanism of action of this drug.
Approved indications
Common side effects
Key clinical trials
- Novel Triple-dose Tuberculosis Retreatment Regimen (PHASE3)
- Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6EH³R³Z CI brief — competitive landscape report
- 6EH³R³Z updates RSS · CI watch RSS
- Institute of Tropical Medicine, Belgium portfolio CI